Trastuzumab binds HER2 on target cells and its Fc engages Fc gamma receptor-bearing effector cells (e.g., NK cells) to mediate antibody-dependent cellular cytotoxicity and lysis; may also contribute via complement activation and HER2 signaling blockade.